Valeant extends savings in new fulfillment agreement with Walgreens
Valeant Pharmaceuticals is forming new fulfillment agreements with Walgreens while indicating it intends to extend this distribution model to additional participating independent retail pharmacies.
"We have listened to what the marketplace is saying and we've taken positive steps to respond. We are pleased to announce both a strategic fulfillment agreement with Walgreens, as well as a new agreement to offer innovator products at generic prices, which is good for consumers, good for physicians and good for the healthcare system," stated Michael Pearson, chairman and CEO Valeant. "Our goal is to create a system that allows prescription medications to be dispensed and insurance claims adjudicated in an efficient manner while allowing physicians to focus their efforts on what matters most: patient care."
"Walgreens is always looking for ways to expand the products and services people want and need, and our agreement with Valeant advances our commitment to creating a patient-led pharmacy experience," said Alex Gourlay, president of Walgreens. "In addition to promoting pharmacist-patient interactions to improve care and medication adherence, this agreement creates a new direct distribution model that we believe will help increase efficiency."
In conjunction with the fulfillment agreement, Valeant will reduce prices of its branded prescription-based dermatological and ophthalmological products by 10%. The reduced pricing will apply to the wholesale list prices of these products and will be phased in over the next six to nine months.
This agreement also covers Valeant's over-the-counter product portfolio.
The agreement will enable consumers to conveniently access Valeant's dermatology and ophthalmology products at a lower out-of-pocket cost from more than 8,000 Walgreens U.S. retail pharmacy locations, as well as participating independent retailers. The 20-year agreement takes effect the first quarter of 2016 and will initially cover Valeant's dermatology products – including Jublia, Luzu, Solodyn, Retin-A Micro Gel 0.08%, Onexton and Acanya Gel – and ophthalmology products including Besivance, Lotemax, Alrex, Prolensa, Bepreve and Zylet.
Valeant and Walgreens hope to expand the relationship to include other therapeutic areas over time, the companies stated.
The agreement is designed to create a more efficient model to help lower costs while ensuring patients have convenient access to the products their doctors prescribe. Patients with commercial insurance can benefit from lower out-of-pocket costs, such as reduced copays, set to be as low as zero for some products initially, and the program will provide convenient access for patients who lack coverage for the products. Because of government regulation, the cost sharing program will not be applicable to patients with government insurance.
Walgreens and Valeant also have entered into a separate agreement under which Valeant will distribute more than 30 branded products, where generics are available, in the dermatology, ophthalmology, gastrointestinal and neurology/other therapeutic areas through Walgreens at generic prices, giving doctors the ability to make the branded product available to patients at generic prices. The reduced pricing for the branded products, which will be available to all patients beginning the second half of 2016, is expected to range from 5% to 95%, or a weighted average price decrease of more than 50%. The agreement covers such products as Aldara, Tiazac and Glumetza.
This program will be available to all patients, including those with government coverage.
Valeant expects the price decreases across both programs, when fully implemented, will provide up to $600 million in annual savings to the healthcare system.
The direct distribution model for Valeant's dermatology and ophthalmology products through Walgreens and independent pharmacies is designed to help reduce costs and administrative processes, yielding savings that can benefit patients and the healthcare system. Independently, Walgreens has retained Leavitt Partners, headed by former U.S. Dept. of Health and Human Services Secretary and former Utah governor Michael Leavitt, to assess the model and evaluate its benefits to patients and markets to ensure it is delivering value.